Purchase this article with an account.
Gianluca Besozzi, Andrea Ferrara, Enrico Epifani, Daniela Intini, Margherita Apruzzese, Antonio Provenzano, Michele Vetrugno; Cataract and Diabetic Macular Edema: a Prospective Comparative Trial Investigating Phacoemusification Associated with Intravitreal Micronized Triamcinolone Acetonide or Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2367.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate macular thickness and visual acuity changes after 1 intravitreal injection of micronized triamcinolone acetonide (mTA) or bevacizumab (B) at the end of phacoemulsification in naïve eyes with cataract and diabetic macular edema (DME)
One hundred naïve eyes with cataract and diabetic macular edema were randomly assigned to receive at the end of phacoemusification 4mg of mTA (Vitreal S, Sooft Italia) or 0.5 mg of B (Avastin, Roche). Comprehensive ophthalmic evaluation was performed preoperatively and at 1, 4, 12 and 24 weeks postoperatively. Main outcome measures included central macular thickness (CMT) and best-corrected ETDRS visual acuity (BCVA). Complications were recorded.
All the patients completed the 24-week study visit. The 2 group did not show significant preoperative differences in CMT (p>0.05) and BCVA (p>0.05). Mean CMT decreased significantly at the end of follow-up in mTA group (p<0.05), but not in B group (p>0.05) Mean BCVA increased significantly in both groups versus baseline (p<0.05). The BCVA gain was greater in mTA group than B group. Intraocular pressure increased only in 4% patients in mTA group. No other complications were recorded
There preliminary data showed that intravitreal mTA is more effective than intravitreal B in management of DME in eyes undergoing cataract phacoemulsification. Further studies with longer follow up are required
This PDF is available to Subscribers Only